Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Als entities : Kalvista pharmaceuticals, inc. save search
KalVista Pharmaceuticals Reports Third Fiscal Quarter Results
Published: 2022-03-10 (Crawled : 16:20) - ir.kalvista.com
KALV | $11.53 -1.03% -1.04% 410K
|
Health Technology
|
| O: -1.06%
H: 2.2%
C: -2.44%
als report results
KalVista Pharmaceuticals Announces Initiation of KVD900 Phase 3 KONFIDENT Clinical Trial
Published: 2022-03-07 (Crawled : 12:00) - ir.kalvista.com
KALV | $11.53 -1.03% -1.04% 410K
|
Health Technology
|
| O: -2.65%
H: 0.0%
C: 0.0%
kvd900 als trial phase 3
KalVista Pharmaceuticals Presents Data Showing Rapid Reduction of Plasma Kallikrein Activity After Oral KVD900 Treatment and Early Symptom Relief From HAE Attacks in Patients
Published: 2022-02-28 (Crawled : 16:20) - ir.kalvista.com
KALV | $11.53 -1.03% -1.04% 410K
|
Health Technology
|
| O: -0.62%
H: 2.63%
C: -0.06%
kvd900 treatment als
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Published: 2022-03-03 (Crawled : 16:20) - ir.kalvista.com
KALV | $11.53 -1.03% -1.04% 410K
|
Health Technology
|
| O: -2.19%
H: 0.0%
C: 0.0%
als nasdaq report grant granted
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Published: 2022-02-02 (Crawled : 16:20) - ir.kalvista.com
KALV | $11.53 -1.03% -1.04% 410K
|
Health Technology
|
| O: 0.79%
H: 4.88%
C: -1.4%
als nasdaq report grant granted
KalVista Pharmaceuticals to Present Data on Oral On-Demand HAE Therapy KVD900 at AAAAI 2022
Published: 2022-02-02 (Crawled : 16:20) - ir.kalvista.com
KALV | $11.53 -1.03% -1.04% 410K
|
Health Technology
|
| O: 0.79%
H: 4.88%
C: -1.4%
kvd900 ema als therapy
KalVista Pharmaceuticals to Present at SVB Leerink Global Healthcare Conference
Published: 2022-02-03 (Crawled : 16:20) - ir.kalvista.com
KALV | $11.53 -1.03% -1.04% 410K
|
Health Technology
|
| O: -2.14%
H: 3.64%
C: 0.0%
health als thc conference svb leerink global
KalVista Pharmaceuticals Announces Publication of Oral HAE Therapy KVD900 Phase 1 Data in Journal of Allergy and Clinical Immunology
Published: 2022-01-24 (Crawled : 13:00) - ir.kalvista.com
KALV | $11.53 -1.03% -1.04% 410K
|
Health Technology
|
| O: -2.93%
H: 4.26%
C: 3.63%
kvd900 als phase 1 therapy immunology phase 2
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Published: 2022-01-04 (Crawled : 15:00) - biospace.com/
KALV | $11.53 -1.03% -1.04% 410K
|
Health Technology
|
| O: 0.86%
H: 1.1%
C: -2.99%
als nasdaq granted grant
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.